WO2003030844A1 - Long-acting hair growth stimulant preparations - Google Patents

Long-acting hair growth stimulant preparations Download PDF

Info

Publication number
WO2003030844A1
WO2003030844A1 PCT/JP2002/010290 JP0210290W WO03030844A1 WO 2003030844 A1 WO2003030844 A1 WO 2003030844A1 JP 0210290 W JP0210290 W JP 0210290W WO 03030844 A1 WO03030844 A1 WO 03030844A1
Authority
WO
WIPO (PCT)
Prior art keywords
minoxidil
preparation
long
hair growth
hair
Prior art date
Application number
PCT/JP2002/010290
Other languages
French (fr)
Japanese (ja)
Inventor
Koji Imamura
Rumi Ochiai
Takako Horie
Susumu Morioka
Shinya Saito
Original Assignee
Taisho Pharmaceutical Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taisho Pharmaceutical Co., Ltd. filed Critical Taisho Pharmaceutical Co., Ltd.
Priority to JP2003533878A priority Critical patent/JP4604489B2/en
Publication of WO2003030844A1 publication Critical patent/WO2003030844A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/494Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
    • A61K8/4953Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom containing pyrimidine ring derivatives, e.g. minoxidil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/34Alcohols
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/84Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions otherwise than those involving only carbon-carbon unsaturated bonds
    • A61K8/86Polyethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/14Drugs for dermatological disorders for baldness or alopecia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q7/00Preparations for affecting hair growth

Definitions

  • the present invention relates to a long-lasting hair growth preparation containing minoxidil as an active ingredient.
  • Conventional technology a long-lasting hair growth preparation containing minoxidil as an active ingredient.
  • Minoxidil has the chemical name 6_ (1-piperidinyl) -2,4-pyrimidindiamine-3-oxide, and its application as a hair restorer is described in US Patent No. 4,139,619. There are many reports on hair growth and hair growth.
  • JP-A-10-265343, JP-A-200-348314, and the like also disclose a long-acting minoxidil preparation that can obtain a sufficient hair-growth effect by application once a day. There have been reports, but better ones were being sought.
  • An object of the present invention is to provide a long-acting minoxidil preparation which can obtain an excellent hair-growth effect by application once a day, and which is excellent in feeling upon use. Disclosure of the invention
  • the present inventors have studied the conditions for maintaining the penetration of minoxidil into the scalp and the feeling of use from the formulation applied to the scalp from the viewpoint of the composition of the minoxidil formulation. It was found that when used as a solvent, sustained permeability could be maintained.
  • the present invention comprises (A) 1 to 5 W / V% of the entire preparation, minoxidil (B) polyethylene glycol, and (C) one or two selected from 1,3-butylene glycol and glycerin. It is a long-lasting hair growth preparation characterized by the following.
  • the amount of minoxidil to be compounded in the present invention is 1 to 5 W / V% of the whole preparation (in the case of an aerosol, in the undiluted solution) (hereinafter “W / V%” may be simply indicated as “%”). And preferably 3 to 5%. If the amount is too small, the hair growth effect is insufficient, and if the amount is too large, minoxidil crystals may precipitate.
  • polyethylene glycol in combination with at least one selected from 1,3-butylene glycol and glycerin.
  • the total compounding amount of those polyhydric alcohols is preferably 5 to 20% of the whole preparation, more preferably 9 to 20%, and still more preferably 9 to 15%. If the amount is too small, it is difficult to obtain a sustained effect, and if the amount is too large, the feeling of use is lowered.
  • the blending amount of the other polyhydric alcohol with respect to 1 part by mass of polyethylene glycol is preferably 0.1 to 10 parts by mass, more preferably 0.5 to 5 parts by mass, and most preferably 1 to 4 parts by mass. .
  • the mixing amount of 1,3-butylene glycol and glycerin is preferably 0.1 to 5 parts by mass, more preferably 0.25 to 5 parts by mass, and more preferably 0.2 to 5 parts by mass with respect to 1 part by mass of polyethylene glycol. 5 to 2.5 parts by weight are most preferred.
  • polyethylene glycol, 1,3-butylene glycol and glycerin can be simultaneously added.
  • the content of serine is preferably 4 to 5% of the whole preparation. Within this range, the solubility of minoxidil is high and the feeling of use is excellent, such as reduced stickiness.
  • the polyethylene glycol used in the present invention preferably has a degree of polymerization of 300 to 4,000, more preferably 300 to 1,000, and particularly preferably polyethylene dalicol having a degree of polymerization of 400. If the degree of polymerization is less than 300, it is difficult to maintain the quality of polyethylene dalicol, and if the degree of polymerization is large, the feeling of use will be poor, and the nature of the preparation will make it difficult to manufacture the preparation.
  • the glycerin used in the present invention is a concentrated glycerin having a content of about 98%, and when a normally used glycerin having a content of about 85% is used, the amount to be blended is determined in consideration of the water content. There is a need.
  • the blending amount of menthyl lactate blended for improving the feeling of use is preferably 0.1 to 5% of the whole preparation. If the amount is less than 0.1%, the feeling of penetration imparted at the time of application is insufficient, and even if the amount is more than 5%, no more feeling of penetration can be expected.
  • ethanol As a solvent for the long-lasting hair growth agent of the present invention, ethanol, water or a mixture thereof is preferable.
  • the amount of ethanol is preferably in the range of about 40 to 82%, and the amount of water is preferably in the range of 5 to 30%.
  • the long-lasting hair growth preparation of the present invention preferably has a pH of 5.5 to 9.5 from the viewpoint of the stability of the main drug component minoxidil, the feeling of use, the feeling of irritation to the skin during use, the permeability of the drug, and the like.
  • the range of 5.5 to 6.5 is more preferred.
  • Normally used acids and bases can be used to adjust the pH, but citric acid and salts are preferred from the viewpoint of preparation and stability of the preparation. Acids, lactic acid, phosphoric acid, and salts thereof, and the like, more preferably, phosphoric acid and its salts, which have little effect on skin.
  • sustained hair growth preparation of the present invention other necessary active ingredients and auxiliary ingredients can be added in addition to the essential ingredients.
  • Pharmaceutical ingredients preferably added to and combined with the sustained-growth hair preparation of the present invention include menthol, vitamin E acetate, pantothenyleethyl ether, hinokitiol, pyridoxine hydrochloride, glycyrrhetinic acid, and diphenhydramine hydrochloride. Selected ingredients can be given. Of these optional ingredients, menthol and pantothenylacetyl are preferred from the viewpoint of a sustained effect.
  • the amount of these optional components to be added is not particularly limited, and can be determined empirically in consideration of the stability of use, the stability of minoxidil, the composition of the solvent system, and the like.
  • a particularly preferred optional ingredient, pantotenyl ester is formulated in an amount of about 0.5 to 1.0% in the final composition to improve the refreshing sensation during application and improve the usability of the whole preparation. It is preferable to do it.
  • various active ingredients and auxiliary ingredients used in general external preparations such as excipients, vasodilators (carpronium chloride, benzyl nicotinate, Sempuli extract, Panax ginseng extract, Pepper tincture, etc.), antihistamines (isotipendyl hydrochloride, etc.), anti-inflammatory agents (guaiazulene, etc.), keratolytic agents (urea, salicylic acid, etc.), fungicides (chlorhexyl dalconate) , Isopropylmethylphenol, quaternary ammonium salt, pyroctone olamine, etc.), moisturizers (sodium hyaluronate, chondroitin sulfate, etc.), various animals and plants (yew, potampi, kanzo, otogiriso, tsutsuj
  • a surfactant which is a component often added to an external preparation, usually affects the skin absorption of minoxidil and may reduce the feeling of use. It is preferable not to substantially add a surfactant.
  • the essential component of the long-acting hair growth preparation of the present invention and, if necessary, other ingredients are blended, and a suitable external use such as a lotion, aerosol, tonic, cream, ointment, gel or the like is carried out in a usual manner. It can be used as a formulation.
  • Test example 1 blood concentration measurement test
  • Wistar rat male (8 weeks old) hair was removed from the abdomen, fixed in a dorsal position under ether anesthesia, and prepared using 14C-minoxidil for a fixed area (2 x 3 cm) of the abdomen 30 L of each of the lotions of Examples 1 to 3 and Comparative Example 1 were applied.
  • Blood is collected from the jugular vein at predetermined times (0.5, 1, 2, 4, 6, 8, 10, 24 hours) with 4 animals per group, and the concentration of minoxidil in the blood is measured by liquid scintillation. The blood minoxidil concentration was measured by measuring with a counter.
  • Minoxidil lg, menthyl lactate lg, macrogol 400 g, glycerin 5 g and ethanol 70 g were mixed and dissolved by stirring, and purified water was added to make a total volume of 10 O mL to prepare a lotion. .
  • a score was given on the feeling of penetration of the drug from the formulation, in a form in which the respondents were asked whether they had a pleasant stimulus.
  • Example 5 30 ml of the lotion agent prepared in Example 4 was filled in an aerosol can, and 70 ml of dimethyl ether was further added to obtain an aerosol agent.
  • the lotion of Example 5 can be similarly used as an aerosol.
  • a liquid preparation was obtained by the usual method using the formulation shown in Table 10.
  • the abdomen of a Wistar rat male (8 weeks old) was dehaired, fixed in a dorsal position under ether anesthesia, and a fixed area of the abdomen (2 x 3 cm) was treated with 14C-minoxidil.
  • Each 30 L of the test lotion prepared according to the formulation shown in 1 was applied.
  • Blood is collected from the jugular vein at predetermined times (0.5, 1, 2, 4, 6, 8, 10, 24 hours) with 4 animals per group, and amino acids in the blood are collected.
  • the blood minoxidil concentration was measured by measuring the xyl concentration in a liquid scintillation counter. The results are shown in Table 12 and FIG.
  • Fig. 1 is a graph showing the change in blood minoxidil concentration in the rat.
  • the vertical axis shows the concentration (ng eq./mL), and the horizontal axis shows the elapsed time.
  • Fig. 2 is a graph showing the results of a usability test with and without the inclusion of menthyl lactate.
  • the vertical axis shows the evaluation results of the usability, and the horizontal axis shows the elapsed time after application.
  • Fig. 3 is a diagram showing the results of a usability test with and without the inclusion of menthyl lactate.
  • the vertical axis shows the evaluation results of the usability and the horizontal axis shows the elapsed time after application.
  • Fig. 4 is a graph showing the change in blood minoxidil concentration in the rat.
  • the vertical axis shows the concentration (ng eq./mL), and the horizontal axis shows the elapsed time.
  • Fig. 5 is a graph showing the change in blood minoxidil concentration in the rat.
  • the vertical axis shows the concentration (ng eq./mL), and the horizontal axis shows the elapsed time.
  • Fig. 6 is a graph showing the change in blood minoxidil concentration in the rat.
  • the vertical axis shows the concentration (ng eq./mL), and the horizontal axis shows the elapsed time.

Abstract

Long-acting minoxidil preparations showing an excellent hair growth stimulating effect when applied once a day and having a favorable feel in using, characterized by containing: (A) from 0.1 to 5 w/v% of minoxidil based on the whole preparation; (B) polyethylene glycol; and (C) one or two members selected from 1,3-butylene glycol and glycerol. Thus, it becomes possible to provide minoxidil preparations whereby a favorable feel in use can be obtained while saving labor in application.

Description

明細書  Specification
持続性育毛製剤 技術分野  Sustained hair growth preparation technology
本発明は、 ミノキシジルを有効成分とする持続性の育毛製剤に関す る。 従来技術  The present invention relates to a long-lasting hair growth preparation containing minoxidil as an active ingredient. Conventional technology
ミノキシジルは化学名を 6_ ( 1 -ピペリジニル)- 2,4-ピリ ミジンジァ ミン- 3-ォキサイ ドと称し、 米国特許第 4, 1 39, 61 9号に育毛剤としての 適応が記載されている他、育毛、養毛作用について多数の報告がある。  Minoxidil has the chemical name 6_ (1-piperidinyl) -2,4-pyrimidindiamine-3-oxide, and its application as a hair restorer is described in US Patent No. 4,139,619. There are many reports on hair growth and hair growth.
ミノキシジル製剤は優れた育毛効果を有するものの、 十分な効果を 発揮するには 1 日に数回の塗布が必要であった。 この様な塗布の手間 を低減させるため、 特開平 1 0- 265343号、 特開 200卜 348314などでは 1 日 1回の塗布で十分な育毛作用を得ることのできる持続性のミノキシ ジル製剤についても報告がされているが、 さらに優れたものが求めら れていた。  Although the minoxidil formulation has an excellent hair-growth effect, it has to be applied several times a day to achieve a sufficient effect. In order to reduce the time and effort for such application, JP-A-10-265343, JP-A-200-348314, and the like also disclose a long-acting minoxidil preparation that can obtain a sufficient hair-growth effect by application once a day. There have been reports, but better ones were being sought.
また、 ミノキシジル製剤で十分な育毛効果を得るためには長期間の 継続的な投与が必要である。 しかし、 十分な使用実感が無いと使用者 が継続使用を断念することが多くなり、 結果的に十分な育毛効果が得 られないなど、 本来の有効性が導き出せないことがあった。 そのため ミノキシジル製剤においては、 使用実感は非常に重要である。  In addition, long-term continuous administration is required to obtain a sufficient hair-growth effect with minoxidil. However, if the user does not have a sufficient feeling of actual use, the user often abandons continuous use, and as a result, a sufficient hair-growth effect cannot be obtained. Therefore, in minoxidil preparations, the feeling of use is very important.
従来のローショ ン剤は、 投与直後にアルコールの揮発に伴う一過性 の使用実感が感じられたものの、 薬剤がじわじわと浸透して行く実感 を感じ難かったり、その効果が持続しているという実感も得難かった。 本発明は、 1 日 1回の塗布で優れた育毛作用を得ることができ、 さ らに使用感にも優れた持続性ミノキシジル製剤を提供することを目的 とする。 発明の開示 With conventional lotion preparations, a temporary feeling of use due to the volatilization of alcohol was felt immediately after administration, but it was difficult to feel the permeation of the drug gradually, or the feeling that the effect was sustained. Was also difficult to obtain. An object of the present invention is to provide a long-acting minoxidil preparation which can obtain an excellent hair-growth effect by application once a day, and which is excellent in feeling upon use. Disclosure of the invention
本発明者らは、 頭皮に塗布した製剤から頭皮へのミノキシジルの浸 透力と使用実感を保持するための条件を、 ミノキシジル製剤の組成面 から検討していたところ、 特定の多価アルコールを組み合わせて溶剤 として使用すると持続した浸透性の保持が図れることを見出した。  The present inventors have studied the conditions for maintaining the penetration of minoxidil into the scalp and the feeling of use from the formulation applied to the scalp from the viewpoint of the composition of the minoxidil formulation. It was found that when used as a solvent, sustained permeability could be maintained.
すなわち本発明は、 (A) 製剤全体の 1〜 5 W/V%のミノキシジル (B ) ポリエチレングリコール、 ならびに ( C ) 1 , 3—ブチレング リコールおよびグリセリンから選ばれる 1種または 2種、 を含有する ことを特徴とする持続性育毛製剤である。  That is, the present invention comprises (A) 1 to 5 W / V% of the entire preparation, minoxidil (B) polyethylene glycol, and (C) one or two selected from 1,3-butylene glycol and glycerin. It is a long-lasting hair growth preparation characterized by the following.
本発明で配合するミノキシジルの配合量は製剤全体 (エアゾール剤 のときは原液中) の 1〜 5 W/V% (以下 「W/V%」 は、 単に 「%」 で示 すことがある) である必要があり、 3〜 5 %が好ましい。 配合量が少 ないと育毛効果が不十分であり、 配合量が多すぎるとミノキシジルの 結晶が析出することがあるからである。  The amount of minoxidil to be compounded in the present invention is 1 to 5 W / V% of the whole preparation (in the case of an aerosol, in the undiluted solution) (hereinafter “W / V%” may be simply indicated as “%”). And preferably 3 to 5%. If the amount is too small, the hair growth effect is insufficient, and if the amount is too large, minoxidil crystals may precipitate.
本発明では 1, 3-ブチレングリコールおよびグリセリ ンから選ばれる 少なく とも 1種とポリエチレングリコールを組み合わせて用いる必要 がある。 それらの多価アルコールの合計配合量は製剤全体の 5〜 2 0 %の配合量が好ましく、 9〜 2 0 %がより好ましく、 9〜 1 5 %がさ らに好ましい。 配合量が少ないと持続した効果が得にく く、 配合量が' 多すぎると使用感の低下を招くからである。  In the present invention, it is necessary to use polyethylene glycol in combination with at least one selected from 1,3-butylene glycol and glycerin. The total compounding amount of those polyhydric alcohols is preferably 5 to 20% of the whole preparation, more preferably 9 to 20%, and still more preferably 9 to 15%. If the amount is too small, it is difficult to obtain a sustained effect, and if the amount is too large, the feeling of use is lowered.
本発明において、 ポリエチレングリコール 1質量部に対する他の多 価アルコールの配合量は、 0. 1〜 1 0質量部が好ましく、 0. 5〜 5質量部がさらに好ましく、 1〜 4質量部が最も好ましい。  In the present invention, the blending amount of the other polyhydric alcohol with respect to 1 part by mass of polyethylene glycol is preferably 0.1 to 10 parts by mass, more preferably 0.5 to 5 parts by mass, and most preferably 1 to 4 parts by mass. .
また、 1 , 3-ブチレングリコールおよびグリセリ ンのそれぞれの配合 量は、 ポリエチレングリコール 1質量部に対して 0. 1〜 5質量部が 好ましく、 0. 2 5〜 5質量部がさらに好ましく、 0. 5〜 2. 5質 量部が最も好ましい。  Further, the mixing amount of 1,3-butylene glycol and glycerin is preferably 0.1 to 5 parts by mass, more preferably 0.25 to 5 parts by mass, and more preferably 0.2 to 5 parts by mass with respect to 1 part by mass of polyethylene glycol. 5 to 2.5 parts by weight are most preferred.
本発明では、 ポリエチレングリコール、 1, 3-ブチレングリコールお よびグリセリ ンを同時に配合することもできるが、 その場合にはダリ セリ ンの配合量は製剤全体の 4〜 5 %が好ましい。この範囲であると、 ミノキシジルの溶解性が高く、 またべたつきが少なくなるなど使用感 にも優れているからである。 In the present invention, polyethylene glycol, 1,3-butylene glycol and glycerin can be simultaneously added. The content of serine is preferably 4 to 5% of the whole preparation. Within this range, the solubility of minoxidil is high and the feeling of use is excellent, such as reduced stickiness.
ここで、 本発明で用いるポリエチレングリコールとしては重合度が 300〜4000のものが好ましく、 300〜1 000のものがさらに好ましく、 重 合度が 4 0 0のポリエチレンダリコールが特に好ましい。重合度が 300 未満であるとポリエチレンダリコールの品質保持が難しく、 重合度が 大きくなると使用感が悪くなり、 また、 その性状から製剤の製造が難 しくなるからである。  Here, the polyethylene glycol used in the present invention preferably has a degree of polymerization of 300 to 4,000, more preferably 300 to 1,000, and particularly preferably polyethylene dalicol having a degree of polymerization of 400. If the degree of polymerization is less than 300, it is difficult to maintain the quality of polyethylene dalicol, and if the degree of polymerization is large, the feeling of use will be poor, and the nature of the preparation will make it difficult to manufacture the preparation.
本発明で用いるグリセリ ンは含量約 9 8 %の濃グリセリ ンのことで あり、 通常用いられる含量約 8 5 %のものを用いる場合にはその含有 する水分量を考慮して配合量を決定する必要がある。  The glycerin used in the present invention is a concentrated glycerin having a content of about 98%, and when a normally used glycerin having a content of about 85% is used, the amount to be blended is determined in consideration of the water content. There is a need.
本発明では、 さらに乳酸メンチルを配合すると、 継続した薬剤の浸 透実感が得られるため使用を継続しやすく、 十分な効果を引き出すた めに有効である。  In the present invention, when further blending of menthyl lactate, a continuous feeling of infiltration of the drug can be obtained, so that it is easy to continue using the drug and it is effective to bring out a sufficient effect.
本発明で使用感向上のために配合する乳酸メンチルの配合量は製剤 全体の 0 . 1 〜 5 %が好ましい。 0 . 1 %未満であると塗布時に与え る浸透感が不十分であり、 5 %より多く配合してもそれ以上の浸透感 は望めないからである。  In the present invention, the blending amount of menthyl lactate blended for improving the feeling of use is preferably 0.1 to 5% of the whole preparation. If the amount is less than 0.1%, the feeling of penetration imparted at the time of application is insufficient, and even if the amount is more than 5%, no more feeling of penetration can be expected.
本発明の持続性育毛剤の溶媒としては、 エタノール、 水またはそれ らの混合液が好ましい。 この場合の配合量はエタノールは 4 0〜 8 2 %程度の範囲、 水は 5〜 3 0 %の範囲が好ましい。 特にエタノールを 配合すると塗布直後のエタノール揮発による良好な使用感が得られる ことから好ましい。  As a solvent for the long-lasting hair growth agent of the present invention, ethanol, water or a mixture thereof is preferable. In this case, the amount of ethanol is preferably in the range of about 40 to 82%, and the amount of water is preferably in the range of 5 to 30%. In particular, it is preferable to add ethanol since a good feeling of use can be obtained by volatilization of ethanol immediately after coating.
本発明の持続性育毛製剤は、 主薬成分のミノキシジルの安定性、 使 用感、 使用時の肌への刺激感、 薬物の浸透性などの点から p H 5 . 5 〜 9 . 5が好ましく、 5 . 5〜 6 . 5の範囲がさらに好ましい。 この p Hの調整には、 通常用いられる酸および塩基を用いることができる が、 製剤の調製や安定性の観点から好ましいものとしてクェン酸、 塩 酸、 乳酸、 リン酸およびそれらの塩などがあげられ、 さらに好ましく は皮膚への影響が少ないリ ン酸およびその塩があげられる。 The long-lasting hair growth preparation of the present invention preferably has a pH of 5.5 to 9.5 from the viewpoint of the stability of the main drug component minoxidil, the feeling of use, the feeling of irritation to the skin during use, the permeability of the drug, and the like. The range of 5.5 to 6.5 is more preferred. Normally used acids and bases can be used to adjust the pH, but citric acid and salts are preferred from the viewpoint of preparation and stability of the preparation. Acids, lactic acid, phosphoric acid, and salts thereof, and the like, more preferably, phosphoric acid and its salts, which have little effect on skin.
本発明の持続性育毛製剤では、 必須成分の他、 他の必要な活性成分 や補助成分を加えることができる。 本発明の持続性育毛製剤に添加、 配合することが好ましい薬効成分としては、 メントール、 ビタミン E アセテート、 パン トテニルェチルエーテル、 ヒノキチオール、 塩酸ピ リ ドキシン、 グリチルレチン酸および塩酸ジフェンヒ ドラミンからな る群より選ばれた成分をあげることができる。 これらの選択成分のう ち、 持続効果の点からはメントールおよびパントテニルェチルェ一テ ルが好ましい。  In the sustained hair growth preparation of the present invention, other necessary active ingredients and auxiliary ingredients can be added in addition to the essential ingredients. Pharmaceutical ingredients preferably added to and combined with the sustained-growth hair preparation of the present invention include menthol, vitamin E acetate, pantothenyleethyl ether, hinokitiol, pyridoxine hydrochloride, glycyrrhetinic acid, and diphenhydramine hydrochloride. Selected ingredients can be given. Of these optional ingredients, menthol and pantothenylacetyl are preferred from the viewpoint of a sustained effect.
これら選択成分の添加量は、 特に制約はなく、 使用感ゃミノキシジ ルの安定性あるいは溶剤系組成等を考慮しながら実験的に定めること ができる。 例えば、 特に好ましい選択成分であるパントテニルェ一テ ルは、 最終組成物中で 0 . 5〜 1 . 0 %程度となるよう配合すると塗 布時の清涼感が向上し、 製剤全体の使用感が向上することから好まし い。  The amount of these optional components to be added is not particularly limited, and can be determined empirically in consideration of the stability of use, the stability of minoxidil, the composition of the solvent system, and the like. For example, a particularly preferred optional ingredient, pantotenyl ester, is formulated in an amount of about 0.5 to 1.0% in the final composition to improve the refreshing sensation during application and improve the usability of the whole preparation. It is preferable to do it.
本発明の持続性育毛製剤においては、 上記した成分の他、 一般の外 用剤に使用される種々の活性成分や補助成分、 例えば、 賦形剤、 血管 拡張剤(塩化カルプロニゥム、ニコチン酸ベンジル、センプリ抽出液、 ォタネニンジンエキス、 トウガラシチンキなど) 、 抗ヒスタミン剤 (塩 酸イソチペンジルなど) 、. 抗炎症剤 (グアイァズレンなど) 、 角質溶 解剤 (尿素、 サリチル酸など) 、 殺菌剤 (ダルコン酸クロルへキシジ ン、 イソプロピルメチルフエノール、 第 4級アンモニゥム塩、 ピロク トンオラミンなど) 、 保湿剤 (ヒアルロン酸ナトリウム、 コンドロイ チン硫酸など) 、 各種動植物 (ィチイ、 ポタンピ、 カンゾゥ、 オトギ リソゥ、 附子、 ビヮ、 力ワラョモギ、 コンフリー、 ァシタパ、 サフラ ン、 サンシシ、 ローズマリー、 セージ、 モッコゥ、 セィモッコゥ、 ホ ップ、 ブラセン夕など) の抽出物、 ビタミン類 (酢酸レチノール、 ァ スコルビン酸、 硝酸チアミン、 シァノコバラミン、 ピオチンなど) 、 抗酸化剤 (ジブチルヒ ドロキシトルエン、 ピロ亜硫酸ナトリウム、 ト コフエロ一ル、 ェデト酸ナトリウム、 ァスコルビン酸、 イソプロピル ガレートなど) 、 溶解補助剤 (アジピン酸ジイソプロピル、 ミ リスチ ン酸イソプロピル、 ポリオキシエチレン硬化ヒマシ油、 ポリソルベー ト類、 プル口ニック類、 各種植物油、 各種動物油、 アルキルグリセリ ルエーテル、 炭化水素類など) 、 代謝賦活剤、 ゲル化剤 (水溶性高分 子など) 、 粘着剤、 香料、 清涼化剤 (ハツ力油、 カンフルなど) 、 染 料などの通常使用される成分を本発明の効果を損なわない範囲で配合 することができる。 In the long-acting hair growth preparation of the present invention, in addition to the above-mentioned components, various active ingredients and auxiliary ingredients used in general external preparations such as excipients, vasodilators (carpronium chloride, benzyl nicotinate, Sempuli extract, Panax ginseng extract, Pepper tincture, etc.), antihistamines (isotipendyl hydrochloride, etc.), anti-inflammatory agents (guaiazulene, etc.), keratolytic agents (urea, salicylic acid, etc.), fungicides (chlorhexyl dalconate) , Isopropylmethylphenol, quaternary ammonium salt, pyroctone olamine, etc.), moisturizers (sodium hyaluronate, chondroitin sulfate, etc.), various animals and plants (yew, potampi, kanzo, otogiriso, tsutsuji, bee, potato sprout, Comfrey, Ashitapa, Safran, Sanshishi , Rosemary, sage, mocco, simocco, hops, brassicae, etc.), vitamins (retinol acetate, ascorbic acid, thiamine nitrate, cyanocobalamin, biotin, etc.), Antioxidants (dibutylhydroxytoluene, sodium pyrosulfite, tocopherol, sodium edetate, ascorbic acid, isopropyl gallate, etc.), solubilizers (diisopropyl adipate, isopropyl myristate, polyoxyethylene hydrogenated castor oil , Polysorbates, pull-mouth nicks, various vegetable oils, various animal oils, alkyl glyceryl ethers, hydrocarbons, etc.), metabolic activators, gelling agents (such as water-soluble polymers), adhesives, fragrances, and fresheners Commonly used components such as (heart oil, camphor, etc.) and dyes can be blended within a range that does not impair the effects of the present invention.
ここで、 通常外用剤に配合されることが多い成分である界面活性剤 は、 ミノキシジルの皮膚吸収に影響を与え、 また使用感を低下させる ことがあるため、 本発明の持続性育毛製剤には実質的に界面活性剤を 配合しない方が好ましい。  Here, a surfactant, which is a component often added to an external preparation, usually affects the skin absorption of minoxidil and may reduce the feeling of use. It is preferable not to substantially add a surfactant.
本発明の持続性育毛製剤必須成分および必要があれば他の配合成分 を配合して、通常の方法でローショ ン剤、エアゾール剤、 トニック剤、 クリーム剤、 軟膏剤、 ゲル剤などの適当な外用製剤にして使用するこ とができる。 発明を実施するための最良の形態  The essential component of the long-acting hair growth preparation of the present invention and, if necessary, other ingredients are blended, and a suitable external use such as a lotion, aerosol, tonic, cream, ointment, gel or the like is carried out in a usual manner. It can be used as a formulation. BEST MODE FOR CARRYING OUT THE INVENTION
以下、 実施例および試験例により、 本発明をさらに具体的に説明す る。  Hereinafter, the present invention will be described more specifically with reference to Examples and Test Examples.
実施例 1〜 3 Examples 1-3
以下の表記載の処方で、精製水以外の成分を混合、攪拌して溶解し、 精製水を加えて全量 1 0 O m Lとして実施例 1 ~ 3および比較例 1 の ローショ ン剤を調製した。 表 1 According to the formulation shown in the table below, components other than purified water were mixed and dissolved by stirring, and purified water was added to make a total amount of 10 OmL to prepare the lotion preparations of Examples 1 to 3 and Comparative Example 1. . table 1
Figure imgf000008_0001
試験例 1 (血中濃度測定試験)
Figure imgf000008_0001
Test example 1 (blood concentration measurement test)
ウィ スター系ラッ ト雄性 ( 8週齢) の腹部を除毛し、 エーテル麻酔 下で背位に固定し、 腹部の一定面積 ( 2 X 3 c m) に対し、 14C-ミ ノ キシジルを用いて調製した実施例 1 〜 3および比較例 1 のローショ ン 剤を各 3 0 L塗布した。 1群 4匹で所定の時間 ( 0 . 5 、 1 、 2 、 4、 6 、 8 、 1 0 、 2 4時間) ごとに頸部静脈より採血し、 血液中の ミノキシジル濃度を液体シンチュレ一シヨ ンカウンタ一で測定する こ とにより血中ミ ノキシジル濃度を測定した。  Wistar rat male (8 weeks old) hair was removed from the abdomen, fixed in a dorsal position under ether anesthesia, and prepared using 14C-minoxidil for a fixed area (2 x 3 cm) of the abdomen 30 L of each of the lotions of Examples 1 to 3 and Comparative Example 1 were applied. Blood is collected from the jugular vein at predetermined times (0.5, 1, 2, 4, 6, 8, 10, 24 hours) with 4 animals per group, and the concentration of minoxidil in the blood is measured by liquid scintillation. The blood minoxidil concentration was measured by measuring with a counter.
結果を表 2 に示した。 また、 本結果の推移を図 1 に示した。 The results are shown in Table 2. Figure 1 shows the transition of the results.
表 2 Table 2
血中濃度推移 (単位 : ng eq. /niL)  Changes in blood concentration (unit: ng eq./niL)
Figure imgf000009_0001
実施例 4
Figure imgf000009_0001
Example 4
ミノキシジル 1 g、 1, 3-ブチレングリコ一ル 5 g、 マクロゴール 4 0 0 5 gおよびエタノール 7 0 gを混合、 攪拌して溶解し、 精製水を 加えて全量 1 0 O m Lとして口一シヨ ン剤を調製した。 実施例 5  Mix 1 g of minoxidil, 5 g of 1,3-butyleneglycol, 400 g of macrogol and 70 g of ethanol, stir to dissolve, add purified water to make a total volume of 10 OmL, and mix. A syrup was prepared. Example 5
ミノキシジル l g、 乳酸メンチル l g、 マクロゴール 4 0 0 5 g、 グリセリ ン 5 gおよびエタノール 7 0 gを混合、 攪拌して溶解し、 精 製水を加えて全量 1 0 O mLとしてローション剤を調製した。 実施例  Minoxidil lg, menthyl lactate lg, macrogol 400 g, glycerin 5 g and ethanol 70 g were mixed and dissolved by stirring, and purified water was added to make a total volume of 10 O mL to prepare a lotion. . Example
実施例 1 と同様にして、 以下の表 3〜表 8に示した組成で、 実施例 および比較例のローショ ン剤を調製した。  In the same manner as in Example 1, the lotions of Examples and Comparative Examples were prepared with the compositions shown in Tables 3 to 8 below.
なお、 表中 「実」 は実施例、 「比」 は比較例を示した。 表 3 In the table, “real” indicates an example, and “ratio” indicates a comparative example. Table 3
実 6 実 7 実 8 実 9 実 1 o ミ ノキシジル 1 g 3 g 5 g 3 g 5 gFruit 6 Fruit 7 Fruit 8 Fruit 9 Fruit 1 o Minoxidil 1 g 3 g 5 g 3 g 5 g
1,3-7'チレンク" リコ-ル 6 g 5 g 5 g 1,3-7 'Tylenek 6g 5g 5g
グリセ リ ン 5 g 5 g ホ。リエチレンク'、 リコ-ル 300 4 g  Glycerin 5 g 5 g e. Reethylenek ', Rekor 300 4 g
ホ。リエチレンク'、 リコ-ル 400 5 g 5 g 5 g 5 g エタ ノ ール 60.05 g 60.05 g 60.05 g 60.05 g 60.05 g 適量 MM E. Lithylene lactone, alcohol 400 5 g 5 g 5 g 5 g Ethanol 60.05 g 60.05 g 60.05 g 60.05 g 60.05 g Appropriate amount MM
乳酸 m里 Lactic acid m
. 精製水 全 lOOmL 全 lOOmL 全 lOOmL 全 lOOmL 全 IGOmL p H 8. 4 8. 4 6. O 6. O 6. O Purified water Total lOOmL Total lOOmL Total lOOmL Total lOOmL Total IGOmL pH 8.4 8. 4 6. O 6. O 6. O
実 1 1 実 1 2 実 1 3 実 1 4 実 1 5 ミ ノキシジル 3 g 3 g 5 g 5 g 5 g 乳酸メ ンチル 1 3 g 0.1 g 1 g 1Actual 1 1 Actual 1 2 Actual 1 3 Actual 1 4 Actual 1 5 Minoxidil 3 g 3 g 5 g 5 g 5 g Menthyl lactate 13 g 0.1 g 1 g 1
1, 3-フ'、チレンク'、 リコ-ル 5 g 1 0 g 8 g 5 g 5 g ホ。リエチレンク" リコ-ル 300 5 g 7 g 1,3-F ', CHIRENK', COLOR 5 g 10 g 8 g 5 g 5 g Lithylene ethylene glycol 300 5 g 7 g
ホ。リエチレンク'、 リコ-ル 400 5 g 5 g 5 g rロピレンク' リコ-ル 2.5g シ" rロピレンク' リコ-ル 2.5g エタ ノ ール 60.05 g 60.05 g 60.05 g 60.05 g 60.05g クェン酸 塩酸 適量 精製水 全 lOOmL 全 lOOmL 全 lOOmL 全 lQOmL 全 lOOmL p H 8. 4 8. 4 6. O 6. O 6. .2 表 5 E. Liethylenek ', Rekol 400 5 g 5 g 5 gr Ropilenk' Rekol 2.5 g Silicon r ropirene 'Rekol 2.5 g Ethanol 60.05 g 60.05 g 60.05 g 60.05 g 60.05 g Cunic acid Hydrochloric acid Appropriate amount Purified water Total lOOmL total lOOmL total lOOmL total lQOmL total lOOmL pH 8.40 8.6.2 O 6.O 6.2 Table 5
実 1 6 実 1 7 実 1 8 ミ ノキシジル 5 g 5 g 5 g 乳酸メ ンチル 1 g 1 3 g グリ セリ ン 5 g 5 s 2 g ホ。リエチレンク' Πコ―ル 400 5  Real 16 Real 17 Real 18 Minoxidil 5 g 5 g 5 g Menthyl lactate 1 g 13 g Glycerin 5 g 5 s 2 g e. Ethylene glycol 'call 400 5
ホ。リエチレンク'リコ-ル 600 5 3 g o ェタ ノ一リレ 60.05 g 60.05 g 60.05 g クェン酸 1 g m里 E. Polyethylene glycol 600 5 3 g o Ethanol 60.05 g 60.05 g 60.05 g Cuenoic acid 1 g m
乳酸  Lactic acid
水酸化ナ ト リ ウム 週里 精製水 全 lQOmL 全 lOOmL 全 lOOmLSodium hydroxide Weekly Purified water Total lQOmL Total lOOmL Total lOOmL
PH 6 · 0 5. 5 6. 5 PH 6.00 5.5 6.5
表 6 Table 6
実 1 9 実 2 0 ミノキシジル 1 g 3 σ 孚し酸メンチリ! 1 ε 1 s Actual 1 9 Actual 2 0 Minoxidil 1 g 3 σ 1 ε 1 s
1 3 フ'チレンク"リコ-ル ら グ Uセ U 1 3 FUJINK "Rikoru et al U U U
ホ。 Uエチレンゥ'リコ-ル 400 E. U Ethylene ゥ -recal 400
ホ°リエチレンゥ'りコール 600 Polyethylene poly call 600
フ°ロ 。レンク"リコール 1 0 sら  Fro. Renk's Recall 10s
シ'、 ロヒ"レンク'、リコール 5 ら a  Shi ', Rohi "Lenk", Recall 5 et a
エタノーリレ 60 05 s 60.05 g クェ、ノ酸 固  Ethanorille 60 05 s 60.05 g
L トール 0 3 ε L Thor 0 3 ε
Vタ ン Eァセ亍-卜 0 08 ε 0 08 ^ ハ。ントテ二ルェチルェ-テル 1 g 1 R ヒノキチオ-ル 0.05 g 0.05 g ク"リチルレチン酸 0.1 0.1 g 塩酸シ"フェンヒド、ラミン 0.1 0.1 g 精製水 全 lOOmL 全 lOOmL p H 6. 0 7. 0 V-tan E-assembly 0 08 ε 0 08 ^ c. 1 g 1 R hinokitiol 0.05 g 0.05 g 0.1 "g lytyl retinoic acid 0.1 g g fenhydride hydrochloride, lamin 0.1 0.1 g Purified water Total lOOmL Total lOOmL pH 6.0 7.0
表 7 Table 7
Figure imgf000013_0001
Figure imgf000013_0001
表 8  Table 8
Figure imgf000013_0002
Figure imgf000013_0002
試験例 2 Test example 2
以下の表 9 に示した処方について使用感試験を行った。  A feeling of use test was conducted for the formulations shown in Table 9 below.
表 9  Table 9
成分名 比較例 9 比較例 10 比較例 11 実施例 21 ミ ノキシジル 3 g 3 g 3 g 3 g Component name Comparative example 9 Comparative example 10 Comparative example 11 Example 21 Minoxidil 3 g 3 g 3 g 3 g
1 , 3-ブチレングリ コール 3 g 3 g グリセリ ン 3 g 3 g リヱチレン リコ-ル 4 0 0 3 g 3 g エタノール 60. 05 g 60. 05 g 60. 05 g 60. 05 乳酸メンチル 5 g 5 g 精製水 全 lQOmL 全 lOOmL 全 lQOmL 全 lOOmL 使用感については、 製剤から薬剤が浸透している実感を、 心地よい 刺激感の有無を回答してもらう形式でスコア付けを行った。 1,3-butylene glycol 3 g 3 g glycerin 3 g 3 g diethylene glycol 400 3 g 3 g ethanol 60.05 g 60.05 g 60.05 g 60.05 Menthyl lactate 5 g 5 g Purification Water Total lQOmL Total lOOmL Total lQOmL Total lOOmL Regarding the feeling of use, a score was given on the feeling of penetration of the drug from the formulation, in a form in which the respondents were asked whether they had a pleasant stimulus.
試験は被験者の一方の側頭部に本発明品、 反対の側頭部に比較品を それぞれ 0. 5mL (被験者 2名) または 1 mL (被験者 1名) 塗布し、 投与 直後から 90分間、 5〜 3 0分毎に被験者にスコアを付けさせて行った。  In the test, 0.5 mL (2 subjects) or 1 mL (1 subject) was applied to one temporal region of the subject and the comparative product to the opposite temporal region, respectively. Subjects were scored every 30 minutes.
スコアは、 5 :強い浸透感を感じた、 4 : 中程度の浸透感を感じた、 3 : 浸透感を感じた、 2 : わずかな浸透感を感じた、 1 : 浸透感を感 じなかった、 の 5段階で評価した。  The scores were 5: strong permeation, 4: moderate permeation, 3: permeation, 2: slight permeation, 1: no permeation , And were evaluated on a scale of 1.
結果を表 1 0、 表 1 1、 図 2および図 3に示した。  The results are shown in Table 10, Table 11, FIG. 2 and FIG.
表 1 0  Table 10
( 1 mL塗布)  (1 mL application)
実験 2  Experiment 2
左側頭部 右側頭部 左側頭部 右側頭部  Left head Right head Left head Right head
時間 比較例 9 比較例 1 0 比較例 1 1 実施例 2 1  Time Comparative Example 9 Comparative Example 1 0 Comparative Example 1 1 Example 2 1
投与直後 5 5  Immediately after administration 5 5
5分後 5 5 ' After 5 minutes 5 5 '
1 0分後 4 4 10 minutes later 4 4
2 0分後 3 4  2 0 minutes later 3 4
3 0分後 2 3  30 minutes later 2 3
4 0分後 2 3  4 0 minutes later 2 3
5 0分後 2 3  5 0 minutes later 2 3
6 0分後 2 3  6 0 minutes later 2 3
9 0分後 2 3 表 1 1 9 0 minutes later 2 3 Table 11
( 0 . 5 mL塗布)  (0.5 mL application)
Figure imgf000015_0001
実施例 2 2
Figure imgf000015_0001
Example 22
実施例 4で調製したローション剤 3 0 m Lをエアゾール缶に充填し さらにジメチルエーテル 7 0 m Lを加えてエアゾール剤とした。また、 実施例 5のローショ ン剤も同様にしてエアゾール剤とすることが可能 である。 30 ml of the lotion agent prepared in Example 4 was filled in an aerosol can, and 70 ml of dimethyl ether was further added to obtain an aerosol agent. In addition, the lotion of Example 5 can be similarly used as an aerosol.
実施例 Example
表 1 0に示した処方で 常法により液剤を得た  A liquid preparation was obtained by the usual method using the formulation shown in Table 10.
表 1 0  Table 10
Figure imgf000016_0001
Figure imgf000016_0001
試験例 2 Test example 2
ウィスター系ラッ ト雄性 ( 8週齢) の腹部を除毛し、 エーテル麻酔 下で背位に固定し、 腹部の一定面積 ( 2 X 3 c m) に対し、 14C-ミノ キシジルを用いて、 表 1 1 に示した処方で調製した被検ローション剤 を各 3 0 L塗布した。 1群 4匹で所定の時間 ( 0. 5、 1、 2、 4、 6、 8、 1 0、 2 4時間) ごとに頸部静脈より採血し、 血液中のミノ キシジル濃度を液体シンチュレーシヨ ンカウンターで測定することに より血中ミノキシジル濃度を測定した。 結果を表 1 2および図 4に示 した。 The abdomen of a Wistar rat male (8 weeks old) was dehaired, fixed in a dorsal position under ether anesthesia, and a fixed area of the abdomen (2 x 3 cm) was treated with 14C-minoxidil. Each 30 L of the test lotion prepared according to the formulation shown in 1 was applied. Blood is collected from the jugular vein at predetermined times (0.5, 1, 2, 4, 6, 8, 10, 24 hours) with 4 animals per group, and amino acids in the blood are collected. The blood minoxidil concentration was measured by measuring the xyl concentration in a liquid scintillation counter. The results are shown in Table 12 and FIG.
表 1 1  Table 11
Figure imgf000017_0001
表 1 2
Figure imgf000017_0001
Table 1 2
血中濃度推移 (単位 : ng eq./mL) 時間 比較例 1 2 実施例 2 5  Change in blood concentration (unit: ng eq./mL) Time Comparative Example 1 2 Example 2 5
(h r ) Mean SE Mean SE  (h r) Mean SE Mean SE
0 0.00 0.00 0.00 0.00  0 0.00 0.00 0.00 0.00
0.5 2.58 0.38 2.96 0.48  0.5 2.58 0.38 2.96 0.48
1 5.19 1.12 6.68 1.05  1 5.19 1.12 6.68 1.05
2 8.00 2.96 9.34 1.51  2 8.00 2.96 9.34 1.51
4 4.23 1.56 9.43 2.42  4 4.23 1.56 9.43 2.42
6 3.29 0.66 8.51 2.12  6 3.29 0.66 8.51 2.12
8 3.01 0.47 7.40 1.56  8 3.01 0.47 7.40 1.56
10 2.91 0.47 6.72 1.21  10 2.91 0.47 6.72 1.21
24 2.24 0.33 5.08 1.27 実施例 · 試験例 24 2.24 0.33 5.08 1.27 Examples and test examples
表 13に示した処方で、 試験例 2 と同様にしてラッ ト血中ミ ノキシジ ル濃度を経時的に測定した。 結果を表 1 4、 表 1 5、 図 5および図 6 に示した。  Using the formulation shown in Table 13, the concentration of minoxidil in rat blood was measured over time in the same manner as in Test Example 2. The results are shown in Tables 14, 15, 15, and 6.
表 1 3  Table 13
Figure imgf000018_0001
Figure imgf000018_0001
g 1 4  g 1 4
(単位: ng eq./mL)  (Unit: ng eq./mL)
比較例 13 実施例 26  Comparative Example 13 Example 26
時間 Mean SE Mean SE  Time Mean SE Mean SE
0 0 0 0 0  0 0 0 0 0
0.5 7.94 5.76 3.77 0.93  0.5 7.94 5.76 3.77 0.93
1 14.85 8.98 7.40 1.49  1 14.85 8.98 7.40 1.49
2 14.44 5.02 8.83 1.59  2 14.44 5.02 8.83 1.59
4 4.60 1.26 7.77 1.23  4 4.60 1.26 7.77 1.23
6 2.86 0.76 5.89 0.75  6 2.86 0.76 5.89 0.75
8 2.17 0.64 5.24 0.69  8 2.17 0.64 5.24 0.69
10 1.72 0.36 4.73 0.68  10 1.72 0.36 4.73 0.68
24 1.20 0.17 3.39 0.58 表 1 5 24 1.20 0.17 3.39 0.58 Table 15
(単位 : ng eq. /mL) (Unit: ng eq./mL)
Figure imgf000019_0001
産業上の利用可能性
Figure imgf000019_0001
Industrial applicability
本発明により、 1 日 1 回の塗布でも優れた効果を有し、 使用実感が 持続する商品性に優れた育毛剤の提供が可能となった。 図面の簡単な説明  According to the present invention, it has become possible to provide a hair restorer which has excellent effects even when applied once a day and has excellent commercial properties that maintains a feeling of actual use. BRIEF DESCRIPTION OF THE FIGURES
図 1 ラッ トの血中ミノキシジル濃度の推移を示した図であり、 縦軸 に濃度 (ng eq./mL) 、 横軸に経過時間を示した。 Fig. 1 is a graph showing the change in blood minoxidil concentration in the rat. The vertical axis shows the concentration (ng eq./mL), and the horizontal axis shows the elapsed time.
図 2 乳酸メンチル配合の有無による使用感試験の結果を示した図で あり、 縦軸に使用感の評価結果、 横軸に塗布後の経過時間を示した。 図 3 乳酸メンチル配合の有無による使用感試験の結果を示した図で あり、 縦軸に使用感の評価結果、 横軸に塗布後の経過時間を示した。 図 4 ラッ トの血中ミノキシジル濃度の推移を示した図であり、 縦軸 に濃度 (ng eq./mL) 、 横軸に経過時間を示した。 Fig. 2 is a graph showing the results of a usability test with and without the inclusion of menthyl lactate. The vertical axis shows the evaluation results of the usability, and the horizontal axis shows the elapsed time after application. Fig. 3 is a diagram showing the results of a usability test with and without the inclusion of menthyl lactate. The vertical axis shows the evaluation results of the usability and the horizontal axis shows the elapsed time after application. Fig. 4 is a graph showing the change in blood minoxidil concentration in the rat. The vertical axis shows the concentration (ng eq./mL), and the horizontal axis shows the elapsed time.
図 5 ラッ トの血中ミノキシジル濃度の推移を示した図であり、 縦軸 に濃度 (ng eq./mL) 、 横軸に経過時間を示した。 図 6 ラッ トの血中ミノキシジル濃度の推移を示した図であり、 縦軸 に濃度 (ng eq./mL) 、 横軸に経過時間を示した。 Fig. 5 is a graph showing the change in blood minoxidil concentration in the rat. The vertical axis shows the concentration (ng eq./mL), and the horizontal axis shows the elapsed time. Fig. 6 is a graph showing the change in blood minoxidil concentration in the rat. The vertical axis shows the concentration (ng eq./mL), and the horizontal axis shows the elapsed time.

Claims

請求の範囲 The scope of the claims
1. (_A) 製剤全体の 1〜 5 W/V%のミノキシジル ( B ) ポリエチレン グリコール、 ならびに ( C ) 1 , 3 —ブチレングリコールおよびダリ セリ ンから選ばれる 1種または 2種、 を含有することを特徴とする持 続性育毛製剤。 1. (_A) 1 to 5 W / V% of the whole preparation containing minoxidil (B) polyethylene glycol and (C) one or two selected from 1,3-butylene glycol and dalyserin A continuous hair growth preparation characterized by the following:
2. (B) 成分および ( C) 成分の合計量が製剤全体の 5〜 2 0 W/V %の配合量である請求の範囲 1記載の持続性育毛剤。 2. The persistent hair restorer according to claim 1, wherein the total amount of the component (B) and the component (C) is 5 to 20 W / V% of the whole preparation.
3. さらに乳酸メンチルを配合した請求の範囲 1記載の持続性育毛製 剤。 3. The long-lasting hair growth preparation according to claim 1, further comprising menthyl lactate.
4. 乳酸メンチルの配合量が製剤全体の 0. 1〜 5 W/ である請求の 範囲 3記載の持続性育毛剤。 4. The persistent hair restorer according to claim 3, wherein the blending amount of menthyl lactate is 0.1 to 5 W / of the whole preparation.
5. 製剤の p Hが 5. 5〜 9. 5の範囲である請求の範囲 1記載の持 続性育毛製剤。 5. The continuous hair growth preparation according to claim 1, wherein the pH of the preparation is in the range of 5.5 to 9.5.
6. さらにパントテニルェチルエーテルを配合した請求の範囲 1記載 の持続性育毛製剤。 6. The long-lasting hair growth preparation according to claim 1, further comprising pantothenyl ethyl ether.
7. パントテニルェチルェ一テルの配合量が製剤全体の 0. 5〜 1 % である請求の範囲 6記載の持続性育毛剤。 7. The long-lasting hair restorer according to claim 6, wherein the amount of the pantotheenyl ester is 0.5 to 1% of the whole preparation.
8. 界面活性剤を実質的に配合しないことを特徴とする請求の範囲 1 記載の持続性育毛剤。 8. The long-lasting hair restorer according to claim 1, wherein a surfactant is not substantially contained.
9. ( A) 製剤全体の 1〜 5 W/V%のミノキシジル ( B ) ポリェチレン グリコ一ル、 ならびに ( C ) 1, 3 —プチレンダリコールおよびダリ セリンから選ばれる 1種または 2種、 を含有する持続性育毛製剤によ る禿、 薄毛の治療方法。 9. (A) 1-5 W / V% minoxidil (B) polyethylene A method for treating baldness and thinning hair with a sustained hair growth preparation comprising a glycol, and (C) one or two selected from 1,3-butylendicol and dalyserin.
1 0 . 育毛剤または発毛剤を製造するための (A ) 製剤全体の 1〜 5 W/V %のミノキシジリレ ( B ) ポリエチレングリコール、 ならびに ( C ) 1 , 3 —ブチレングリコ一ルおよびグリセリ ンから選ばれる 1種また は 2種、 からなる組成物の使用。 10. (A) 1-5 W / V% minoxidilyl (B) polyethylene glycol, and (C) 1,3-butyleneglycol and glycerin for the production of a hair restorer or a hair restorer Use of a composition consisting of one or two selected from the group consisting of:
PCT/JP2002/010290 2001-10-04 2002-10-02 Long-acting hair growth stimulant preparations WO2003030844A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2003533878A JP4604489B2 (en) 2001-10-04 2002-10-02 Sustainable hair growth preparation

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2001-308711 2001-10-04
JP2001308711 2001-10-04
JP2002-73699 2002-03-18
JP2002073699 2002-03-18

Publications (1)

Publication Number Publication Date
WO2003030844A1 true WO2003030844A1 (en) 2003-04-17

Family

ID=26623706

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2002/010290 WO2003030844A1 (en) 2001-10-04 2002-10-02 Long-acting hair growth stimulant preparations

Country Status (2)

Country Link
JP (1) JP4604489B2 (en)
WO (1) WO2003030844A1 (en)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006176446A (en) * 2004-12-22 2006-07-06 Lion Corp Composition for scalp and hair
JP2009519936A (en) * 2005-12-16 2009-05-21 マレック,シェーン Carrier composition for topical administration and therapeutic formulation containing the same
JP2014214098A (en) * 2013-04-24 2014-11-17 ロート製薬株式会社 Composition for external application containing minoxidil
JP2017226692A (en) * 2017-09-05 2017-12-28 ロート製薬株式会社 Minoxidil containing external composition
JP2018048104A (en) * 2016-01-22 2018-03-29 大正製薬株式会社 Composition for external use
JP2018199739A (en) * 2018-10-02 2018-12-20 ロート製薬株式会社 Minoxidil containing external composition
JP2020189883A (en) * 2020-08-24 2020-11-26 ロート製薬株式会社 Minoxidil containing external composition

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63301811A (en) * 1987-01-28 1988-12-08 Taisho Pharmaceut Co Ltd Minoxidil-containing ointment
JPS6468309A (en) * 1987-09-09 1989-03-14 Shiseido Co Ltd Trichogenous and hair-tonic agent
JPS6468308A (en) * 1987-09-09 1989-03-14 Shiseido Co Ltd Trichogenous and hair-tonic agent
JPH1112136A (en) * 1997-06-27 1999-01-19 Taisho Pharmaceut Co Ltd Minoxidil-formulated aerosol
JP2000198719A (en) * 1998-10-29 2000-07-18 Taisho Pharmaceut Co Ltd Hair growing agent
JP2000239139A (en) * 1999-02-16 2000-09-05 Shiseido Co Ltd Skin cosmetic

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000505095A (en) * 1996-08-23 2000-04-25 花王株式会社 Aqueous skin cosmetics
JPH10279439A (en) * 1997-03-31 1998-10-20 Kureha Chem Ind Co Ltd Trichogenous agent
JPH10279438A (en) * 1997-03-31 1998-10-20 Kureha Chem Ind Co Ltd Trichogenous composition
JP3192626B2 (en) * 1997-12-19 2001-07-30 高砂香料工業株式会社 Hair restorer
JP2000219619A (en) * 1999-02-01 2000-08-08 Shiseido Co Ltd Cosmetic

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63301811A (en) * 1987-01-28 1988-12-08 Taisho Pharmaceut Co Ltd Minoxidil-containing ointment
JPS6468309A (en) * 1987-09-09 1989-03-14 Shiseido Co Ltd Trichogenous and hair-tonic agent
JPS6468308A (en) * 1987-09-09 1989-03-14 Shiseido Co Ltd Trichogenous and hair-tonic agent
JPH1112136A (en) * 1997-06-27 1999-01-19 Taisho Pharmaceut Co Ltd Minoxidil-formulated aerosol
JP2000198719A (en) * 1998-10-29 2000-07-18 Taisho Pharmaceut Co Ltd Hair growing agent
JP2000239139A (en) * 1999-02-16 2000-09-05 Shiseido Co Ltd Skin cosmetic

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006176446A (en) * 2004-12-22 2006-07-06 Lion Corp Composition for scalp and hair
JP2009519936A (en) * 2005-12-16 2009-05-21 マレック,シェーン Carrier composition for topical administration and therapeutic formulation containing the same
JP2014214098A (en) * 2013-04-24 2014-11-17 ロート製薬株式会社 Composition for external application containing minoxidil
JP2018048104A (en) * 2016-01-22 2018-03-29 大正製薬株式会社 Composition for external use
JP2018162319A (en) * 2016-01-22 2018-10-18 大正製薬株式会社 Composition for external use
JP7070192B2 (en) 2016-01-22 2022-05-18 大正製薬株式会社 External composition
JP2017226692A (en) * 2017-09-05 2017-12-28 ロート製薬株式会社 Minoxidil containing external composition
JP2018199739A (en) * 2018-10-02 2018-12-20 ロート製薬株式会社 Minoxidil containing external composition
JP2020189883A (en) * 2020-08-24 2020-11-26 ロート製薬株式会社 Minoxidil containing external composition

Also Published As

Publication number Publication date
JP4604489B2 (en) 2011-01-05
JPWO2003030844A1 (en) 2005-01-20

Similar Documents

Publication Publication Date Title
JP5561264B2 (en) Hair growth composition
JP2005314323A (en) Hair growth formulation
JP4940527B2 (en) Sustainable hair growth composition
WO1998032417A1 (en) Persistent hair tonic
JPH10265343A (en) Sustained release hair growing agent
WO2003030844A1 (en) Long-acting hair growth stimulant preparations
JP2002326913A (en) Hair growing composition
EP1416923B1 (en) Reduction of hair growth
JPH1192378A (en) Hair tonic liquid for external use
EP0276151B1 (en) Dissolved composition of [benzo-1,2,4-thiadiazine]-1,1-dioxide for hair germination and hair growth promotion.
JP2810040B2 (en) Hair restorer for scalp and hair
JPH07316022A (en) Hair tonic
JP2001278750A (en) New hair-growing agent
JPWO2001076540A1 (en) Hair restoration composition
JP2546813B2 (en) Hair nourishing cosmetics
JPH10279437A (en) Hair cosmetic
US10543227B2 (en) Hair growth composition
JP2001288031A (en) Additive for hair-growing agent and hair-growing agent composition
EP1416906B1 (en) Reduction of hair growth
JP4892786B2 (en) Sustainable hair growth preparation
JPH0629165B2 (en) [Benzo-1,2,4-thiadiazine] -1-dioxide derivative-dissolved composition
JP2021123586A (en) Pharmaceutical composition for external use
JP2003012468A (en) Promoter for restoration and growth of hair
JP3088835B2 (en) Hair restorer
JPH10218736A (en) Hair grower

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR LC LK LR LS LT LU LV MA MD MG MN MW MX MZ NO NZ OM PH PL PT RU SD SE SG SI SK SL TJ TM TN TR TZ UA UG US UZ VC VN YU ZA ZM

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2003533878

Country of ref document: JP

122 Ep: pct application non-entry in european phase